公开(公告)号：US09775834B2

公开(公告)日：2017-10-03

申请号：US14867773

申请日：2015-09-28

申请人： Veloxis Pharmaceuticals A/S

发明人： William J. Polvino

IPC分类号： A61K31/44 ,  A61K31/436 ,  A61K31/5377 ,  A61K39/395 ,  A61K9/20 ,  A61K9/00 ,  A61K45/06 ,  A61K39/00

CPC分类号： A61K31/436 ,  A61K9/0053 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2031 ,  A61K9/2036 ,  A61K9/2054 ,  A61K9/2077 ,  A61K31/5377 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505

摘要： The present invention relates to a method of suppressing organ rejection in a patient receiving an organ transplant by initiating oral treatment with a once-daily extended release tacrolimus dosage form, for example, at an initial dose of from about 0.15 to about 0.20 mg/kg/day within 24 or 48 hours following transplantation. The once-daily extended release tacrolimus dosage form (i) provides low fluctuation and/or swing of tacrolimus, (ii) provides a significantly lower Cmax than an immediate release formulation of tacrolimus while providing the same or greater area under the curve (AUC), (iii) releases the tacrolimus substantially in the colon and/or the lower ileum, (iv) releases at most 63.5% of the tacrolimus in the dosage form at the 12 hour time point, or (v) any combination of any of the foregoing.

公开(公告)号：US09775811B2

公开(公告)日：2017-10-03

申请号：US15413554

申请日：2017-01-24

申请人： PURDUE PHARMA L.P. ,  PURDUE PHARMACEUTICALS L.P.

发明人： William H. McKenna ,  Richard O. Mannion ,  Edward P. O'Donnell ,  Haiyong H. Huang

IPC分类号： A61K9/20 ,  A61K9/28 ,  A61K31/485 ,  A61K9/00 ,  B29C37/00 ,  B29B7/02 ,  B29C43/00 ,  B29C43/02 ,  B29C43/52 ,  B29C71/00 ,  B29B7/88 ,  B29C35/16 ,  B29K71/00 ,  B29L31/00 ,  B29K105/00

CPC分类号： A61K9/28 ,  A61J3/005 ,  A61J3/06 ,  A61J3/10 ,  A61K9/0002 ,  A61K9/0053 ,  A61K9/1641 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2077 ,  A61K9/209 ,  A61K9/2095 ,  A61K9/284 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/2893 ,  A61K31/485 ,  A61K45/06 ,  A61K47/10 ,  A61K47/34 ,  B29B7/02 ,  B29B7/88 ,  B29C35/045 ,  B29C35/16 ,  B29C37/0025 ,  B29C43/003 ,  B29C43/02 ,  B29C43/52 ,  B29C71/00 ,  B29C71/009 ,  B29C2035/046 ,  B29C2035/1658 ,  B29K2071/02 ,  B29K2105/0035 ,  B29K2105/251 ,  B29K2995/0088 ,  B29L2031/753

摘要： The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

公开(公告)号：US20170274088A1

公开(公告)日：2017-09-28

申请号：US15619637

申请日：2017-06-12

申请人： Tris Pharma, Inc.

发明人： Ketan Mehta ,  Yu-Hsing Tu

IPC分类号： A61K31/135 ,  A61K31/137 ,  A61K31/155 ,  A61K31/192 ,  A61K31/216 ,  A61K31/24 ,  A61K31/4402 ,  A61K31/4458 ,  A61K31/485 ,  A61K45/06 ,  A61K47/14 ,  A61K47/32 ,  A61K9/00 ,  A61K9/10 ,  A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61K9/50

CPC分类号： A61K47/585 ,  A61K9/0053 ,  A61K9/0056 ,  A61K9/0095 ,  A61K9/10 ,  A61K9/14 ,  A61K9/1635 ,  A61K9/1664 ,  A61K9/167 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/4866 ,  A61K9/5021 ,  A61K9/5026 ,  A61K31/135 ,  A61K31/137 ,  A61K31/155 ,  A61K31/192 ,  A61K31/216 ,  A61K31/24 ,  A61K31/4402 ,  A61K31/4458 ,  A61K31/485 ,  A61K45/06 ,  A61K47/14 ,  A61K47/32 ,  A61K47/6921 ,  A61K47/6927 ,  A61K47/6933

摘要： A particulate, modified release barrier coated drug-cation exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. Methods of making and products containing this coated complex are described.

公开(公告)号：US09763920B2

公开(公告)日：2017-09-19

申请号：US14934908

申请日：2015-11-06

申请人： Veloxis Pharmaceuticals A/S

发明人： Per Holm

IPC分类号： A61K31/436 ,  A61K9/10 ,  A61K9/16 ,  A61K9/28 ,  A61K31/00 ,  A61K31/4745 ,  A61K31/439 ,  A61K9/00 ,  A61K9/20

CPC分类号： A61K31/436 ,  A61K9/0053 ,  A61K9/10 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1641 ,  A61K9/1652 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2095 ,  A61K9/2846 ,  A61K9/2893 ,  A61K31/00 ,  A61K31/439 ,  A61K31/4745 ,  Y10S514/885

摘要： A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability.

公开(公告)号：US09750703B2

公开(公告)日：2017-09-05

申请号：US15045975

申请日：2016-02-17

申请人： Purdue Pharma L.P.

发明人： Haiyong Hugh Huang

IPC分类号： A61K9/20 ,  A61K9/24 ,  A61K31/485 ,  A61K9/00 ,  A61K9/28

CPC分类号： A61K9/2077 ,  A61K9/0053 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/28 ,  A61K31/485

摘要： In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.

公开(公告)号：US20170246161A1

公开(公告)日：2017-08-31

申请号：US15355140

申请日：2016-11-18

申请人： Orexo AB

发明人： Andreas Fischer

IPC分类号： A61K31/485 ,  A61K9/20 ,  A61K9/00

CPC分类号： A61K31/485 ,  A61K9/0056 ,  A61K9/006 ,  A61K9/14 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2095 ,  A61K31/4748

摘要： There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.

公开(公告)号：US09744137B2

公开(公告)日：2017-08-29

申请号：US11897940

申请日：2007-08-31

申请人： Avinash Nangia ,  Daya D. Verma ,  Jules Jacob

发明人： Avinash Nangia ,  Daya D. Verma ,  Jules Jacob

IPC分类号： A61K9/22 ,  A61K9/28 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61K9/50 ,  A61K31/357

CPC分类号： A61K9/2846 ,  A61K9/1635 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2086 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/5073 ,  A61K31/357

摘要： The present invention is directed to pharmaceutical compositions that allow for once-daily or alternate day dosage forms of topiramate. The proposed delayed/extended release single dosage form is equivalent to the immediate-release multiple dose daily regimen, and upon administration, provides steady state blood levels of topiramate. Formulations with increased bioavailability and improved pharmacokinetics are disclosed. A once-a-day administration of topiramate is advantageous over the multiple dose regimen both in terms of patient compliance and reduced adverse events, thus providing better treatment of the conditions for which the topiramate is indicated.

公开(公告)号：US09744136B2

公开(公告)日：2017-08-29

申请号：US14024360

申请日：2013-09-11

申请人： Purdue Pharma L.P.

发明人： Haiyong Hugh Huang

IPC分类号： A61K9/20 ,  A61K9/24 ,  A61K31/485 ,  A61K9/00 ,  A61K9/28

CPC分类号： A61K9/2077 ,  A61K9/0053 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/28 ,  A61K31/485

摘要： In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.

公开(公告)号：US09687451B2

公开(公告)日：2017-06-27

申请号：US12661670

申请日：2010-03-22

申请人： Orapin P. Rubino ,  David M. Jones

发明人： Orapin P. Rubino ,  David M. Jones

IPC分类号： A61K9/16 ,  A61K9/20 ,  A61K31/138 ,  A61K31/192

CPC分类号： A61K9/1676 ,  A61K9/1611 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2077 ,  A61K31/138 ,  A61K31/192

摘要： A compressed tablet of a pharmaceutical compound which contains uncoated pellets containing a pharmaceutical compound, where the uncoated pellets are dispersed in a matrix containing the pellets and a swellable polymer.

公开(公告)号：US20170165245A1

公开(公告)日：2017-06-15

申请号：US15442017

申请日：2017-02-24

申请人： Alkermes Pharma Ireland Limited

发明人： Sean Cunningham ,  Seamus Mulligan ,  Michael Myers

IPC分类号： A61K31/4409 ,  A61K9/20

CPC分类号： A61K31/4409 ,  A61K9/20 ,  A61K9/2054 ,  A61K9/2077 ,  A61K31/44 ,  A61K47/12 ,  A61K47/14 ,  A61K47/38 ,  A61K47/44

摘要： A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.